Both the Protocols and Procedures of therapy center inside San Javier Hospital, Guadalajara , are certified by COFEPRIS (Comisión Federal Para la Protección de los Riesgos Sanitarios).
SARASOTA, Fla., May 12, 2014 (GLOBE NEWSWIRE) -- Caribbean International Holdings (Pink Sheets:CIHN) through its subsidiary, Regenerative BioScience, Inc., ("RBS") previously announced on May 7, 2014, that it was opening new treatment locations in Guadalajara, Mexico, and Cabo St Lucas; In an update today, it was announced that the location in Guadalajara was the prestigious San Javier Hospital - Guadalajara. This will be the Company's second location that will offer stem cell therapies, in addition to its facilities in the Dominican Republic.
The hospital houses some of the most accomplished researchers/therapists in the stem cell field.
The Company plans to add other locations for its stem cell therapies/services, in order to give the patients more geographic options to choose from.
Dr. Gonzalez stated: "In a quest to offer patients better services and options, Regenerative BioScience is identifying key locations that patients can travel to and obtain excellent stem cell therapy care. One of those locations we have established lies in the beautiful, historical city of Guadalajara, Mexico. We are finalizing negotiations with the private state of the art Hospital San Javier in Guadalajara, Mexico." ( http://www.sanjavier.com.mx/en/ )
Dr. Gonzalez went on to say: "Most importantly, the Hospital San Javier is approved for stem cell therapies by the FDA equivalent in Mexico, Comisión Federal Para la Protección de los Riesgos Sanitarios (COFEPRIS). We are finalizing our medical staff, which will bring you the patient quality, caring and excellent service in a secure and ideal setting."
Steven Swank, Chairman and CEO of Caribbean International Holdings, stated, "We are finalizing our medical staff, which will bring our patients a superior level of quality, caring and excellent service in a secure and ideal setting as part of our goal to make our stem cell therapies a comfortable experience. We also want to make sure that our patients have options for their therapy. This location in Guadalajara is ideal and it's a great city to visit following their therapy. We will soon be naming our medical director for this facility, which will assure that our patients obtain excellent quality care, but we are not done. Regenerative Biosciences will soon add other locations for stem cell therapy in order to give the patient even more geographic options to choose from."
About The Company:
Caribbean International Holdings, Inc. is a holding company for Regenerative BioScience, Inc. ("RBSI"). The Company subsidiary RBSI is focused on helping individuals to protect and ensure their future quality of life through Adult Stem Cell Incubation and the practice of regenerative medicine in the United States and the Dominican Republic.
RBSI's mission is not only to allow patients to store their Stem Cells for future use, but also perform patient funded stem cell therapies for degenerative diseases such as MS, Arthritis, Degenerative Heart Diseases, Diabetes and a host of experimental therapies in the brain trauma disease sector including CTE. The goal is to become a global leader in establishing protocols that can be patented and utilized to heal patients around the world.
Adult stem cells work as the repairmen of the body by replenishing and regenerating damaged tissues and cells. Certain conditions have shown marked improvement when treated with adult stem cells taken from the patient's own body. Regenerative BioScience is a revolution in healthcare using a patient's own adult stem cells.
For more information go to: http://www.regenerativebioscience.com/index.html
About: Rafael Gonzalez, Ph.D.
Dr. Gonzalez has expertise in degenerative disorders involving the spinal cord and has extensive experience in stem cell culture and biology from human embryonic, pre-natal and adult sources. Prior to joining DaVinci Biosciences, Dr. Gonzalez served as a Research Scientist at PrimeGen Biotech where he was responsible for the design and execution of experiments involving adult (bone marrow, menstrual blood, adipose) and pre-natal stem cells (neural, bone marrow, liver, gonadal) for potential clinical application. Dr. Gonzalez was also responsible for developing PrimeGen's pre-clinical stem cell/spinal cord injury model.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available on at http://www.sec.gov .
Investor Contact: BioScience (941) 924-9400
